Source / episode info
- **Episode:**38
- **Title:**Divine Intervention Episode 38 – Neuro Pharmacology Part 1.
- **Published:**2018-06-21
- Source:Episode page
One-liner
This episode provides a comprehensive review of neuropharmacology, covering basal ganglia circuitry, the pathophysiology of movement disorders like Parkinson's and Huntington's disease, metabolic pathways (PKU), and drug mechanisms for treating conditions ranging from Alzheimer's to Serotonin syndrome.
High-yield summary
- Basal Ganglia Circuitry: The direct pathway promotes movement via D1 receptors ({G}_s-coupled); the indirect pathway inhibits movement via D2 receptors ({G}_i-coupled). Dysfunction in these circuits underlies most movement disorders.
- Parkinson's Treatment Triad: Due to low dopamine, treatment involves: 1) L-DOPA (precursor), 2) Carbidopa (peripheral DDC inhibitor), and 3) MAO-B inhibitors (e.g., Selegiline) to prevent breakdown of central dopamine.
- PKU Metabolism: Phenylalanine -> Tyrosine -> DOPA -> Dopamine. The pathway requires B6 for the conversion of DOPA to Dopamine, and BH_4 for the initial step (Phenylalanine hydroxylase).
- Genetic Movement Disorders: Myotonic dystrophy is associated with CTG repeats and maternal inheritance; Huntington's disease involves CAG repeats and selective destruction of the indirect basal ganglia pathway, leading to hyperkinesia.
- Serotonin Syndrome: Caused by excessive serotonergic activity (e.g., SSRIs + MAOIs). Key symptoms include fever, altered mental status, and prominent myoclonus; treated with an antagonist like Cyproheptadine.
Learning objectives
- Describe the anatomical connections and functional roles of the basal ganglia pathways (direct vs. indirect).
- Differentiate the pathophysiology, genetics, and clinical presentation of major movement disorders (PD, HD, Hemiballismus).
- Outline the metabolic pathway for amino acid conversion (Phenylalanine -> Dopamine) and identify associated deficiencies.
- Correlate drug mechanisms with neurotransmitter systems (e.g., MAO-B inhibition, DDC inhibition, 5-HT antagonism).
- Recognize the clinical presentation and management of toxic/metabolic syndromes (Serotonin Syndrome, PKU).
Board exam buzzwords